Diprogenta

/ MSD

Adolescents and Adults: Apply a thin film to the affected skin areas twice daily and carefully rub in. Frequency of application should be determined by the physician according to the severity of the condition. For some patients, adequate maintenance therapy may be achieved with less frequent application.
Duration of therapy varies depending upon the extent and location of disease and patient response. However, if clinical improvement is not achieved by two to three weeks, diagnosis should be reviewed.
Children 2 to 12 years old: Apply a thin film to only the affected skin and carefully rub in. Apply a sufficient amount no more frequently than twice daily with at least 6-12 hours between applications. Application to face, neck, scalp, genitalia, rectal area, and skin flexures should be applied under medical supervision. Limit treatment to no more than 5 to 7 days.

Dermatoses complicated by secondary infection.

Hypersensitivity to the active substances or to any of the excipients used in the preparation as well as to aminoglycoside antibiotics (cross allergy to gentamicin).
Skin infections [of viral, bacterial (incl. TB) and fungal aetiology], vaccine reactions, skin ulcers and acne are contraindicated in the case of locally applied corticosteroids. Facial application is not recommended in the presence of rosacea or perioral dermatitis.
Diprogenta should not be applied to mucous membranes, to the eyes or the area surrounding the eyes.

See prescribing information for full details.

See prescribing information for full details.

Phenytoin, barbiturates, carbamazepine, aminoglutethimide, rifampicin. Thiazide and loop diuretics, cardiac glycosides, acetazolamide. Oral hypoglycemics, insulin. Antihypertensives, anabolic steroids, ophthalmic idoxuridine, NSAID?, aspirin, other salicylates, coumarin anticoagulants, vaccines, estrogens. Other aminoglycosides, vancomycin, some cephalosporins. Loop diuretics, anticholinesterases, lactitol. Muscle relaxants, b-lactam antibiotics.

Pregnancy: In animal studies, topical application of corticosteroids was shown to have a teratogenic effect. There are no data on its use in human pregnancies.
Aminoglycosides cross the placental barrier and may harm the foetus if administered to pregnant women. There have been reports of total, irreversible, bilateral, congenital deafness in infants whose mothers received aminoglycosides (including gentamicin) during pregnancy. Sufficient
data on the use of topically applied gentamicin during pregnancy is lacking.
During pregnancy, Diprogenta should only be used in cases where it is absolutely necessary.
Lactation: It is not known whether topically applied corticosteroids pass into breast milk. However, systemically available corticosteroids are excreted in breast milk. It is not known whether gentamicin passes into breast milk. If applied to the breasts, Diprogenta may not be used by nursing mothers.